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SUMMARY 
Nicotine intake, menstrual and smoking withdrawal symptomatology, and baseline cortisol and 
MHPG were assessed in nine women smokers under conditions of ad lib smoking and overnight 
abstinence in three menstrual phases (early follicular, mid-to-late follicular, and late luteal). A trend 
towards higher nicotine intake (p<0.10) was observed in the mid-to-late follicular phase. Although 
menstrual symptomatology was not significantly elevated during the smoking abstinence condition 
overall, abstinence appeared to prevent the normal reduction in symptomatology during the mid-to- 
late follicular phase that occurred under conditions of ad lib smoking. Menstrual and withdrawal 
symptoms were highly correlated, and both were most pronounced during the late luteal/abstinence 
condition. The smoking-specific item "craving" reflected this pattern, though in attenuated form, 
suggesting that the observed exacerbation of withdrawal symptomatology was not simply due to 
generalized dysphoria, as queried in both instruments. MHPG was significantly elevated in the late 
luteal phase, whereas cortisol was significantly higher during ad lib smoking than during abstinence 
and tended to be highest in the mid-to-late follicular phase. Further investigation will be needed to 
determine the functional significance of these findings for understanding and treating smoking in 
women. 
INTRODUCTION 
OVER THE PAST SEVERAL YEARS, there has been growing recognition that systematic hormonal 
fluctuations associated with the menstrual cycle have an impact not only on reproductive 
biology but also upon numerous other aspects of mood, behavior, and cognitive function (e.g., 
Magos, 1987). Because psychoactive substances, by definition, alter mood or performance, the 
idea that discretionary drug use may vary as a function of menstrual phase has considerable 
face validity. But, although several investigators have attempted to demonstrate such a phe- 
nomenon for a variety of  drugs, including caffeine (Schechter et al., 1989), alcohol (Mello, 
1986; Schechter et al., 1989), and marijuana (Griffin et al., 1986), the only persuasive evidence 
advanced to date has been in the presence of the premenstrual syndrome (PMS) ( Mello, 1986). 
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Other appetitive responses, however, most notably craving for food and food intake (Pliner & 
Fleming, 1983; Tomelleri & Grunewald, 1987; Laessle et al., 1990), have been convincingly 
demonstrated to increase during the premenstrual phase of the normal menstrual cycle in 
healthy volunteers. 
Attempts to test the hypothesis that nicotine self-administration varies systematically in 
response to menstrual phase have produced mixed results: (1) Steinberg and Cherek (1989) 
studied nine women during 2-hr sessions conducted 5 days/week over two consecutive men- 
strual cycles. Based on automated measures, most subjects increased mean puff number and/or 
total puff duration per session during menses, compared with the premenstrual phase (the 
5 days immediately preceding onset of flow) and with all other days combined (with no further 
phase distinctions). (2) Mello et  al. (1987) studied cigarette smoking in 24 women given 
access to alcohol for 21 days in an inpatient setting. Seventeen of the 24 (70%) increased 
smoking, indicated by a decreased inter-cigarette interval during the premenstruum (undefined). 
When the analysis was limited to the 19 women who had concurrent access to alcohol during 
the premenstruum (to eliminate access/lack of access to alcohol as a possible confound), 14 
(74%) exhibited increased smoking during that period. All women reported increased psycho- 
logical discomfort during the premenstruum. (3) O'Hara et  al. (1989) studied withdrawal 
symptoms in 22 premenopausal smokers enrolled in a behavioral smoking cessation program. 
For nine of these women, the scheduled "quit day" happened to fall during the follicular phase 
of the cycle (day 1 to day 15). For the remaining 13, it fell during the luteal phase (day 15 
through the day prior to onset of menses). Subjects who quit during the luteal phase showed 
significantly higher scores on a questionnaire rating withdrawal symptoms 24 and 72 hr after 
quitting. For the group overall, highly significant correlations were found at 24, 48, and 72 hr 
between withdrawal scores and ratings of menstrual distress. 
Unfortunately, because of design limitations and discrepant definitions of phase, these 
studies raise as many questions as they answer. Although two of the three (Mello et al., 1987; 
O'Hara et al. ,  1989) suggest increased smoking and increased withdrawal symptomatology 
during the latter part of the cycle, it is difficult to specify the phase associated with increases in 
smoking or to relate these studies to one another. By contrast, the study by Steinberg and 
Cherek (1989) showed the highest level of smoking to occur during menses rather than during 
the premenstruum. Since day 1 of the menstrual cycle was not separated out from the remain- 
der of the menses, however, it is unclear how much smoking in response to dysmenorrhea 
might have contributed to this effect. (It has been suggested that nicotine may relieve men- 
strual cramps [Andersch & Milsom, 1982; Backon, 1989], a phenomenon that deserves study in 
its own right.) Interpretation of the study by Mello et al. (1987) is complicated by their simul- 
taneous manipulation of the availability of alcohol. O'Hara et al. (1989) compared absolute 
post-cessation withdrawal scores, without correcting for pre-cessation scores. Moreover, the 
failure of the withdrawal scale to be sensitive to abstinence effects calls the validity of the main 
dependent variable into question. None of these three studies (Mello et al., 1987; O'Hara et al., 
1989; Steinberg & Cherek, 1989) included any attempt to verify menstrual phase with 
hormonal measures, an omission that may have some bearing on the conflicting findings. For 
example, in the study by O'Hara et al. (1989), women who quit smoking on days 12-17 may 
have been pre- or post-ovulatory, depending on their average cycle length, bringing the follicu- 
lar and luteal ascriptions into question. Furthermore, measures of plasma nicotine were not taken 
in the studies on smoking, and topographical parameters are known to be inadequate indices of 
nicotine intake (Pomerleau et al., 1989b). 
In an effort to clarify and extend our understanding of these issues, we studied nine women 
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smokers under conditions of  ad lib smoking and abstinence, in three hormonally verified phases 
of  the menstrual cycle: (1) The early follicular (EF) phase, during which most  women are in 
menses and when es t rogen and proges terone are usually low, was chosen  as a test o f  the 
findings o f  Steinberg and Cherek (1989). (2) The mid-to-late follicular (M/LF) phase was 
chosen because it was regarded as likely to be affectively and behaviorally "neutral" (Schechter 
et al., 1989; Mitchell et al., in press). (3) The late luteal phase (LL), when estrogen and proges- 
terone levels are beginning to drop and "premenstruar '  symptoms tend to occur, was chosen as 
a stringent test o f  the findings of  Mello et al. (1987) and O ' H a r a  et al. (1989). Menstrual 
symptomatology, withdrawal symptomatology, and, on the ad lib smoking days, nicotine intake 
after smoking a single cigarette were assessed. Our hypothesis was that menstrual phase would 
affect nicot ine intake and smoking-re la ted affect ive variables (e.g., n icot ine withdrawal).  
Although the mixed findings in the literature regarding the nature and existence o f  differences 
in either intake or  s y m p t o m a t o l o g y  precluded extensive speculat ion about  the underlying 
hormonal  mechanisms,  we also measured basal levels of  cortisol and 3-methoxy-4-hydrox-  
yphenylglycol (MHPG) in an effort to assess whether corticosteroid and/or central noradrener- 
gic activity (using MHPG as a marker; Peyrin, 1990) were associated with menstrual phase, 
smoking condition (abstinence vs. ad lib smoking),  and /o r  subsequent nicotine intake. 
SUBJECTS AND METHODS 
Subjects 
Nine female smokers were recruited from the community through local newspaper advertisements to partici- 
pate in this study. To be eligible, a subject was required (1) to be between 20 and 39 yr old, (2) to smoke an 
average of at least 15 cigarettes per day, (3) to be in good health and not on any prescription medications, (4) to 
be neither underweight nor markedly obese (Body Mass Index [BMI] between 18 and 27 kg/m2; Kraemer et al., 
1990), (5) not to be using oral contraceptives or an IUD, (6) not to be pregnant or at risk for becoming pregnant, 
(7) to have no complaints or history of treatment for PMS; and (8) to menstruate on a regular basis, with 
monthly cycles averaging between 26 and 35 days. Subjects also were excluded for recent psychiatric ill- 
nesses. Over 100 women responded to our advertisements, 24 of whom met the eligibility requirements with 
respect to age, BMI, cycle length, smoking rate, etc. Of these 24 women, 15 were excluded because of schedul- 
ing difficulties, failure to keep appointments, or our inability to establish a patent line for blood withdrawal. 
Definition and verification of menstrual phase 
Subjects were studied twice during each of three menstrual phases known to vary in terms of ovarian steroid 
milieu and menstrual symptomatology: (1) The EF phase was defined as day 2 through day 5 of the menstrual 
cycle. Day 1 was avoided because of the potential confounding effect of dysmenorrhea. (2) The M/LF phase 
was the time period following menses and prior to the pre-ovulatory luteinizing hormone (LH) surge. Subjects 
were scheduled between day 6 and day 11. (3) The LL phase was defined as the 4 days prior to menses. A 
home test kit developed to aid in achieving or avoiding pregnancy (either OvuQUICK, Monoclonal Antibodies, 
San Diego, CA, or Clearplan Easy, Whitehall Laboratories, New York, NY) was used to pinpoint the LH surge, 
which precedes ovulation by 24-36  hr and the onset of next menses by approximately 14 days, and the 
subjects were scheduled accordingly. To verify that the cycle under investigation was indeed ovulatory, the 
subjects were asked to bring first morning urine samples to the laboratory on days 7-9  following the LH surge, 
and a qualitative assay of pregnanediol glucoronide, a progesterone metabolite, was performed. 
Definition and verification of abstinence from smoking 
At the beginning of each session, subjects were tested for expired carbon monoxide with the VITALO- 
GRAPH-EC50 monitor to determine compliance with the abstinence requirement. On non-smoking days, values 
above 15 ppm would have disqualified subjects for that day's session. Compliance was subsequently verified 
by nicotine assay. 
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Subjective instruments 
The Hughes-Hatsukami Withdrawal Scale (Hughes & Hatsukami, 1986) was modified by inclusion of 
bipolar endpoints, to minimize the bias towards dysphoria inherent in the unipolar version. Each of the 16 
items was rated on a scale of -5 through +5, with possible total scores ran~ng from -80 to +80. The Woods 
Menstrual Symptom Severity List (Mitchell et al., in press) identifies 33 items that contribute to phase differ- 
ences in symptom severity. Items are scored on a scale of 0 (none) through 4 (severe); overall score can range 
from 0-132. In the version used in our study, the 33 scored items were embedded in a 51-item questionnaire 
designed to downplay our interest in specifically "premenstrual" symptomatology. 
Assays 
Blood samples were collected in Vacutainer tubes containing EDTA to prevent clotting and immediately 
stored in crushed ice. Following the session, samples were centrifuged at 4 ° C. Plasma aliquots were frozen at 
-80 ° C. Nicotine, cotinine, MHPG, and cortisol were analyzed by M. Hariharan, Ph.D., in the Psychiatry 
Department Research Assay Support Laboratory. Estradiol (E) and progesterone (P) were analyzed in the 
Pediatric Endocrine Laboratory of C. S. Mott Children's Hospital under the supervision of Inese Beitins, M.D. 
Assays of nicotine and cotinine were performed by high performance liquid chromatography (HPLC) 
(Hariharan et al., 1988). This method requires about 1 ml of biological sample. The isocratic HPLC unit 
utilized a Cls reverse-phase column and a mobile phase of citric acid-phosphate buffer and phenylimidazole as 
the internal standard. Average coefficient of variation (CV) for the assay was 6.5% for nicotine, with a lower 
detection limit of 1 ng/ml. 
Plasma cortisol was measured by competitive protein binding assay. Average interassay CV was 6.3%, and 
inn'assay CV was 5.95%, with a 0.5 I.tg/dl lower limit of detection. 
MHPG was analyzed by an HPLC method (Hariharan et al., 1989) that employs coulometric detection with 
iso-MHPG as the internal standard. The detection limit of the assay is 0.1 I.tg/1. The interassay CV for a sample 
with a mean MHPG concentration of 3.84 I.tg/l was 5.2%, and the average recovery was 37%. 
Plasma E (England et al., 1974) and P (Niswender, 1973) were measured by radioimmunoassay (RIA). For 
E, the interassay CV averaged 8%, the intraassay CV averaged 4%, and the sensitivity was 5 pg/ml. For P, the 
interassay CV averaged 5%, the intraassay CV averaged 5%, and the sensitivity was 20 pg/ml. 
Urinary test kits 
OvuQUICK provides a qualitative home test of LH in late morning urine. In a clinical study of 19t speci- 
mens in 25 cycles reported by the manufacturer, OvuQUICK was compared to both a qualitative EIA and a 
quantitative RIA in detecting the LH surge. OvuQUICK identified the LH surge the same day as did EIA 96% of 
the time (one day earlier for the remaining 4%), and the same day as did RIA 98% of the time. Clear'plan Easy 
is a similar home test of LH in urine collected at least 4 hr after previous urination. In a clinical study of 54 
consecutive patients, Clearplan predicted ovulation within one day of the serum LH surge as measured by RIA 
in 82-88% of cases and within 2 days in 89-96% of cases (Gudgeon et al., 1990). ProgestURINE (Mono- 
clonal Antibodies, San Diego, CA) is a qualitative assay of pregnanediol glucoronide (PDG) in the first morning 
urine during the mid-luteal phase. The assay sensitivity is 3 I.tg/ml. In a study of 324 urine specimens from 28 
menstrual cycles reported by the manufacturer, overall correlation with urinary PDG measured by RIA was 
92%. In a similar comparison with 92 samples from 28 menstrual cycles, overall correlation with serum P by 
RIA was 93%. 
Procedure 
Each subject attended an orientation session during her M/LF phase, during which the requirements of the 
study were reviewed, written informed consent was obtained, instruction in the use of the urine test kits was 
provided, the subject's height and weight were measured, and baseline questionnaires were completed. The 
subjects were not informed of the purpose of the study. Although they were clearly aware of our interest in the 
menstrual cycle, smoking, and smoking abstinence, queries made following each subject's participation in the 
study gave no indication that they brought any expectations to the study regarding possible interactions of these 
variables. Study sessions were conducted at mid-day (starting between 1000h and 1230h, standard for each 
subject, so that each subject's test time varied by less than an hour across the 6 study days) on two consecutive 
weekdays (ad lib smoking vs. overnight abstinence sessions) in each of the three identified menstrual phases. 
For three of the six sessions, once in each menstrual phase, the subject smoked ad lib prior to that day's session. 
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For the other three sessions, the subject was asked to abstain from smoking for 12 hr preceding the session. 
To minimize the impact of possible order effects, subjects were randomly assigned to one of two smoking con- 
dition sequences (ad lib smoking day first vs. abstinence day first) and one of three menstrual phase sequences 
(EF first, M/LF first, LL first), a total of six possible sequences. 
The subjects was seated in a reclining chair separated from the experimenter by a 5'x4' partition. An 
indwelling catheter was inserted into a forearm vein and connected to a heparinized 1 -m long infusion-exfusion 
tubing. This line was run through a 3-in hole in the partition. On smoking days only, to standardize the 
nicotine deprivation period, the subjects smoked one usual-brand cigarette immediately after insertion of the 
line (min 0). Between min 0 and 30, the subjects completed the smoking withdrawal and menstrual symptoma- 
tology questionnaires. When they finished, they were permitted to read magazines. At min 30, the subjects 
were asked to smoke one usual-brand cigarette. 
Blood withdrawal occurred as unobtrusively as possible at 1 min, 15 min, 30 rain, and 35 min following 
insertion of the line (min 0). The samples taken at 1 min, 15 min, and 30 min were later pooled for assay of 
baseline E and P (to control to some degree for episodic secretion). Blood withdrawn during the 30-min 
sampling period was also assayed for cortisol, MHPG, and, on smoking days only, pre-smoking nicotine levels. 
Blood withdrawn at 35 min was assayed for nicotine, providing post-smoking levels on smoking days and 
"baseline" levels on abstinence days. Following completion of the session and withdrawal of the line, the 
subjects participated in a brief taste-testing procedure to provide data for a larger database on sweet taste prefer- 
ence in women smokers, exsmokers, and nonsmokers (Pomerleau et al., 1991). 
The data were analyzed by two-way repeated measures factorial ANOVA, with two levels of smoking condi- 
tion (ad lib smoking vs. overnight abstinence) and three levels of menstrual phase (EF, M/I..F, and LL). 
Nicotine intake was assessed only once during each phase and was analyzed by one-way ANOVA. Pearson 
product-moment correlation coefficients were calculated for the major variables. Because too little is known 
about most of the variables under investigation to permit the formulation of directional hypotheses, two-tailed 
significance tests were used throughout. 
RESULTS 
The subjects ranged in age f rom 23 to 34 yr  ( m e a n + S D = 2 7 . 2 + 4 . 1  yr) and had a BMI 
ranging from 1 9 - 2 7  ( m e a n + S D = 2 2 . 4 + 2 . 6 ) .  They scored a mean (+SD) of  6.6 + 1.8 on the 
Fagers t rom Tolerance Questionnaire,  an index of  nicot ine dependence (Fagerstrom, 1978; 
Fagers t rom & Schneider ,  1989),  charac te r iz ing  them as modera t e ly  dependent  smokers  
(Pomerleau et al., 1989a). No subject exceeded an average daily intake of  600 mg caffeine or 
an average weekly intake of  150 g ethanol (10 drinks). 
Confirmation of  abstinence and menstrual phase 
All subjects succeeded in meeting the criteria for overnight abstinence, as measured by CO 
and subsequently verified by plasma nicotine levels o f  < 10 ng/ml .  Mean baseline nicotine 
levels for the three abstinence days (mean+SEM) were 2.0+0.6,  1.6 +0.9,  and 2.6 + 0.7 ng/ml. 
Comparable values for the three ad lib smoking days were 20 .8+2 .6 ,  20 .9+2 .4 ,  and 21 .6+  
2.1 ng/ml. As expected, significant differences emerged for smoking condition (abstinence vs. 
ad lib smoking),  but not for menstrual phase (F2A6=0.30, p=NS).  No interaction effects were 
detected (F2A6 = 0.03, p=NS).  
Difficulties in predicting and scheduling the 18 LL sessions (two LL sessions for each of  
nine subjects) resulted in the following protocol deviations: (1) Four of  the 18 LL sessions sub- 
sequently proved to have been scheduled slightly earlier than intended (7 to 5 days prior to the 
onset o f  menses).  (2) A fifth LL session was anomalous,  because onset of  menses occurred 
earlier than predicted 2 mo  in a row. Since insurmountable  logistical problems prevented 
further rescheduling, the session had to be run shortly after the onset of  menses. (3) Because 
one subject was unable to attend her LL/abstinence session as originally scheduled, it had to be 
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postponed until the next month, again following the prediction and verification procedures 
described above. Thus, means for the LL phase actually include data for four sessions that fell 
1-3 days earlier than specified by the protocol, one session that fell a few hours later than spec- 
ified, and one LL/abstinence session that, though falling within the prescribed interval, was nan 
during a different cycle from her LL/smoking session. All data were included in the analysis. 
There was a significant main effect of phase for P and a trend towards a significant phase effect 
for E. No smoking condition or interaction effects were detected. Fig. 1 presents the mean 
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follicular follicular 
FIo. I. Levels of estradlol and progesterone measured in three pooled p lasma samples  
after ad  lib smoking and overnight abstinence for each of three menst rual  phases  (mean_+ SEM; n= 9]. 
Nicotine intake 
Mean nicotine increments (post- minus pre-smoking levels) on smoking days were 9.0 
+ 1.7, 11.5 + 1.8, and 9.4 + 2.2 ng/ml for the EF, M/LF, and LL phases, respectively. There was 
a trend toward a significant difference among these means (F2:6=2.86, p<0.10). The nicotine 
increments for the three smoking days were highly corrrelated, with coefficients ranging from 
0.80 (p<0.05) to 0.88 (p<0.01). 
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Early follicular Mid - to - late Late luteal 
tollicular 
FIG. 2. Scores  on  Woods M e n s t r u a l  S y m p t o m  
Severity Checklist {total of 33 Items, each scored 
1-4) af ter  a d  llb smok ing  and  overnight  abst i -  
nence for each of three mens t rua l  phases  (mean_+ 
SEM; n = 9]. 
Menstrual  and withdrawal symptomatology 
Scores on the menstrual symptomatology 
questionnaire are presented in Fig. 2. These data 
place six subjects in the range of high symptom 
severity for the M/LF phase and five for the LL 
phase, as defined by Mitchell et al. (in press), 
with six subjects showing phase differences sug- 
gestive of PMS. No significant main effect for 
smoking condition was detected. A trend toward 
a significant main effect for menstrual phase 
emerged (F2,16=2.82, p<0.10),  as did a trend 
towards a significant phase × smoking condition 
interaction (F2,16 = 3.23, p < 0.10). 
Scores on the nicotine withdrawal question- 
naire are presented in Fig. 3. A highly signifi- 
cant main effect for smoking condition was 
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detected for withdrawal scores (FL8= 11.93, p<0.05), as expected, with scores in the ovemight 
abstinence condition consistently exceeding those in the ad lib smoking condition. A trend 
toward a significant main effect for menstrual phase emerged (F2.16=3.15, p<0.10), as did a 
trend toward a significant phase x smoking condition interaction (F2o 16 = 3.32, p < 0.10). 
For all sessions, the menstrual symptomatology and withdrawal symptomatology question- 
naires were highly correlated, with coefficients among the 6 study days ranging from 0.64 
(p<0.10) to 0.95 (p<0.001). For most subjects, a high degree of within-subject correlation 
between these two scales was observed as well, with correlation coefficients for the nine 
subjects across the six study conditions being -0.31 (NS), -0.14 (NS), 0.67 (NS), 0.80 (p< 0.10), 
0.80 (p<0.10), 0.81 (p<0.05), 0.90 (p<0.05), 0.91 (p<0.05), and 0.97 (p<0.01). For both 
scales, overall menstrual and withdrawal symptoms were most pronounced during the LL phase 
under conditions of abstinence. As shown in Fig. 4, the smoking-specific item of craving, in 
addition to the expected significant elevations for smoking condition (F1,8= 18.84, p<0.01), 
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fo41icular 
FIG. 3. Scores on a bipolar version of the Hughes° 
Hatsukaml  Smoking Withdrawal Scale (modified) 
(range of possible scores: -80 to +80) after ad lib 
s m o k i n g  and  overn igh t  a b s t i n e n c e  for each of 








Eady follicular Mid - to - late Late luteal 
follicular 
FXC. 4. Scores on  t he  c rav ing  i t em  (range o f  pos- 
sible scores: -5  to  +5) In  t he  b ipo la r  vers ion  o f  the 
H u g h e s - H a t s u k a m l  S m o k i n g  W i t h d r a w a l  Sca le  
(modified) af ter  ad  lib s m o k i n g  and  overn igh t  
abs t i nence  for each  of t h r ee  m e n s t r u a l  p h a s e s  
(mean + SEM; n = 91. 
MHPG and cortisol 
MHPG levels for the six sessions are presented in Fig. 5 (complete data available for eight 
subjects). Statistical analysis showed a significant main effect for menstrual phase (F2.14= 5.45, 
p<0.05). Newman-Keuls tests revealed that LL levels were significantly higher than EF levels 
(p<0.05) and M/LF levels (p<0.001), with no significant difference between the latter two 
phases. No significant effects for smoking condition or phase × smoking condition interaction 
were detected. MHPG levels for the 6 days were highly correlated, with coefficients ranging 
from 0.64 (p<0.10) to 0.95 (p<0.001). 
Cortisol levels for the six sessions are shown in Fig. 6 (complete data available for eight 
subjects). Analysis revealed significant effects for smoking condition (F13 = 15.17, p< 0.01), 
with ad lib smoking levels (30 min after the previous cigarette) exceeding those under conditions 
of overnight abstinence. A trend towards a significant menstrual phase effect also emerged 
(F2,14=2.97,p<0.10). No significant phase × smoking condition interaction was detected. Unlike 
for MHPG, no systematic pattern of intercorrelations among the 6 days was detected for cortisol. 
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4 ~ Smoking day 
E ~  At~tJnence day 
12  
J 
-o 1 0  
'~_ 8 
8 
Early f~lteul~" Mid - to  - late Late l u t e a l  E a r l y  f o l l i c u l a r  M i d  - to  - l a t e  L a t e  l u t e a l  
f o l l i c u l a r  t o l l i ~ l a t  
Fro. 5. Plasma MHPG levels after a d  lib smoking 
and overnight abst inence for each of three men- 
strual phases  (mean+ SEM; n = 8). 
FIG. 6, Plasma cortisol levels after a d  lib smoking 
and overnight abst inence for each of three men-  
strual  phases  (mean_+ SEM: n = 8). 
Correlation among variables 
Correlation coefficients were calculated in an effort to determine the possible relationship 
between baseline variables and subsequent nicotine intake. Basal MHPG levels were negatively 
correlated with subsequent nicotine intake, with correlation coefficients for the EF, M/LF, and 
LL phases being -0.63 (p < 0.10), -0.67 (p < 0.05), and -0.60 (p < 0.10), respectively. No signif- 
icant or systematic correlations of basal cortisol level, menstrual symptomatology, or with- 
drawal symptomatology with subsequent nicotine intake were detected. Neither MHPG nor 
cortisol showed any consistent pattern in predicting menstrual or withdrawal symptomatology. 
Plasma E and P levels were not systematically correlated with any other dependent variable. 
D I S C U S S I O N  
As expected, marked phase effects were observed for E and P. Consistent with the fact that 
several subjects were tested 1-3 days earlier than planned in the LL phase, mean p values 
exceeded the expected values for day -4 through onset of menses (usually < 2 ng/ml).  
Consequently, ascription of our findings (or in some instances our lack of findings) to specifi- 
cally "premenstrual" factors must be made with caution. 
Unfortunately, our study amplifies rather than resolves inconsistencies already in the litera- 
ture regarding differential smoking in response to menstrual phase (Mello et al., 1987; O'Hara 
et al., 1989; Steinberg & Cherek, 1989), since our findings suggest the possibility of a slight 
increase in nicotine intake during the M/LF phase, a phase characterized by the smallest degree 
of menstrual symptomatology. Unlike ours, none of the previous studies included biochemical 
verification of nicotine intake. On the other hand, our sample was small, the observed differ- 
ences in intake were modest and fell short of significance, and our measures were based on the 
results of smoking a single, nondiscretionary cigarette. 
It is worth noting that nicotine intake on a given day is one of the best predictors of nicotine 
intake on any other day, as indicated by the strong intercorrelations observed for nicotine intake 
for the 3 smoking days. The consistency with which smokers self-administer nicotine has been 
demonstrated (Benowitz, 1988) but is sometimes forgotten in attempts to uncover situational 
determinants of smoking. In fact, situational variations in smoking are probably best under- 
stood as superimpositions on the addictive cycles manifested by individual smokers. 
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Our subjects' overall menstrual symptomatology ratings were high in comparison with 
those reported by Mitchell et al. (in press). Since treatable PMS was an exclusion criterion, 
however, we attribute these findings to extensive differences in the circumstances under which 
the test was administered, rather than to any unexpected incidence of PMS in our subjects. 
Ratings of menstrual symptomatology on the smoking days showed the expected "on/off" 
pattern, with the lowest scores prevailing during the M/LF phase. Though no significant eleva- 
tion in symptomatology was observed for the abstinence condition overall, our data can be 
interpreted to suggest that the "on/off" pattern is disrupted by the stressful effects of smoking 
abstinence, resulting in more constant and chronic symptomatology across the cycle. 
The strong correlations between menstrual symptomatology and withdrawal symptomatol- 
ogy replicate those of O'Hara et al. (1989) and similar findings noted briefly by Allen et al. 
(1991). Though this finding is to some extent an artifact resulting from the extensive overlap 
between the individual items on the questionnaires, it may be that women smokers themselves 
confuse withdrawal symptoms with menstrual symptoms, or experience them in an additive or 
potentiated manner. Both menstrual and withdrawal symptoms were most pronounced during 
the LL/abstinence condition. The smoking-specific item "craving" also reflected this pattern in 
attenuated form, suggesting that the observed exacerbation of withdrawal symptomatology 
during the LL/abstinence condition was not simply a result of generalized dysphoria queried in 
both instruments. These results, taken together, may have treatment implications in that cessa- 
tion may produce more discomfort, or possibly require more "inoculation" against relapse, 
during the LL phase. 
The finding of elevated MHPG levels in the LL phase is consistent with the pattern reported 
in the literature for normal subjects whose smoking status was not reported (DeLeon-Jones et 
al., 1978) and for women with PMS (Parry et al., 1991). Overnight abstinence from smoking 
did not significantly affect MHPG levels. The apparent ability of MHPG levels to predict subse- 
quent nicotine intake, with lower levels being associated with higher nicotine intake, is in 
keeping with the idea that smokers may "use" nicotine to stimulate catecholamine release 
(Westfall & Watts, 1964; Carruthers, 1976; McCarty, 1982), and that catecholamine depletion 
as reflected in reduced levels of MHPG may trigger increased smoking. The fact that MHPG 
levels did not differ between the smoking and nonsmoking conditions, however, indicates that a 
few hour of nicotine abstinence does not produce noticeable differences in catecholamine 
metabolic activity. Moreover, there was no evidence of an increase in smoking in response to 
the "stress" of premenstrual or withdrawal symptomatology. 
Studies of the effects of abstinence on cortisol levels in smokers have produced conflicting 
results, with some investigators having reported an increase and others a decrease (cf. Hughes 
et al., 1990, for review). The present study showed a consistent decrease in cortisol following 
approximately 12-hr abstinence, though the difference reached significance only in the LL 
phase. Since the cortisol sample in the present study was withdrawn 30 min after the previous 
cigarette, however, the possibility that the observed elevation on the ad lib smoking days was 
an acute response to a recent cigarette, rather than to chronic exposure to nicotine, cannot be 
ruled out. The trend toward a significant phase effect for cortisol, with levels being highest in 
the M/LF phase, is consistent with previous findings for nonsmokers (Gennazini et al., 1975; 
Tam et al., 1985) and for women with PMS (Parry et al., 1991). The coincidence of peak 
smoking with peak cortisol is consistent with the hypothesis that smokers increase nicotine 
intake under conditions when cortisol is elevated to compensate for corticosteroid-mediated 
decreases in the sensitivity of the nicotine receptor (Pauly et al., 1988; Pomerleau & Pomerleau, 
1990). Since both "peaks" represent statistical trends only, and since no correlation between 
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cortisol and subsequent nicotine intake was detected, such an interpretation must be regarded 
with caution. 
Because the present study was exploratory in nature, replication in larger samples and over 
multiple cycles, with stratification of subjects by degree of menstrual symptomatology and 
nicotine dependence, is desirable. Failure to detect significant correlations among various 
variables (e.g., cortisol and subsequent nicotine intake) must be interpreted with particular 
caution, as our sample was too small to provide adequate statistical power. Inclusion of non- 
smoking controls to provide baseline data might help clarify the chronic hormonal effects of 
nicotine in smokers. 
The need for further investigation in this area is not academic. Since the release of Surgeon 
General Luther "Ferry's landmark report publicizing the hazards of cigarette smoking (USPHS, 
1964), its prevalence in American men declined much more sharply (from 50.2% in 1965 to 
31.7% in 1987) than in women (from 31.9% to 26.8%) (USDHHS, 1989). I f  current trends 
persist, smoking rates for women will exceed those for men by the mid-1990s (USDHHS, 
1989). Rates of  ini t iat ion have dropped much fas ter  among  men than among  women  
(USDHHS, 1989). Women seem to quit with greater difficulty, possibly because they are treated 
with methods less appropriate to them (USDHHS, 1980; Stoto, 1986; Marlatt et al., 1988; Blake 
et al., 1989) and relapse more frequently than do men (Gritz, 1980). Although women, as 
major users of the health care system, have probably been adequately represented in treatment 
trials (e.g., Hooper, 1990), much of the basic behavioral and biological research on which these 
treatment strategies are based has been conducted in men. It is to be hoped that studies such as 
the present one will contribute to the identification of factors specific to smoking in women that 
could be used as the basis for the development of more effective, targeted treatment strategies. 
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